Neutral
Regeneron Pharmaceuticals (REGN) reported Q4 2025 revenue of US$3.9 billion and EPS of US$8.21, with shares trading around US$686.83. The company's ne...
Neutral
Certuity LLC significantly reduced its stake in Regeneron Pharmaceuticals Inc. by 70.7% in Q4, selling 1,536 shares and leaving 637 shares valued at a...
Regeneron Pharmaceuticals recently achieved significant milestones, including FDA accelerated approval for Otarmeni, expanded pediatric approval for D...
Bullish
TD Cowen has raised its price target for Regeneron Pharmaceuticals (REGN) to $960 from $880, reiterating a Buy rating ahead of the company's fiscal Q1...
Bullish
Regeneron Pharmaceuticals outlined its C5 complement development strategy, highlighting the combination of cemdisiran and pozelimab to achieve tunable...
Bullish
The Arizona State Retirement System reduced its stake in Regeneron Pharmaceuticals (NASDAQ:REGN) by 5.7% in Q4 2025, now holding 29,232 shares valued ...
Bullish
The White House is expected to announce a drug pricing deal with Regeneron Pharmaceuticals, making it the final company among 17 targeted by President...
Neutral
Cantor Fitzgerald has reissued an "Overweight" rating for Regeneron Pharmaceuticals (NASDAQ:REGN) with an $800 price target, suggesting a 4.42% upside...
Bullish
Sanofi and Regeneron's Dupixent has received U.S. approval as the first biologic medicine for children under 12 with uncontrolled chronic spontaneous ...
Regeneron Pharmaceuticals (REGN) is a US biotechnology company with a market value of US$76.7 billion. Despite mixed short-term share price performanc...
Regeneron Pharmaceuticals (NasdaqGS:REGN) announced positive Phase 2 results for its bispecific antibody, lunsekimig, in treating moderate to severe a...
Neutral
Asset Management One Co. Ltd. has reduced its stake in Regeneron Pharmaceuticals, Inc. by 10.5%, selling 6,358 shares and now holding 54,181 shares va...
Regeneron Pharmaceuticals (REGN) has seen a 31.4% return over the last year, but its 3-year performance shows an 8.3% decline. Despite this, Simply Wa...
Bullish
Sanofi and Regeneron's drug, Dupixent, has received approval in the European Union to treat moderate-to-severe chronic spontaneous urticaria (CSU) in ...
Bullish
Australia-based Telix Pharmaceuticals and US-based Regeneron Pharmaceuticals have announced a strategic collaboration to co-develop and co-commerciali...
This article headline indicates that Regeneron Pharmaceuticals (REGN) shares experienced a drop in value, despite the announcement of positive results...
Bullish
Telix Pharmaceuticals and Regeneron Pharmaceuticals have announced a strategic collaboration to co-develop and co-commercialize next-generation radiop...
Neutral
Wall Street Zen has downgraded Regeneron Pharmaceuticals (NASDAQ:REGN) from a "Buy" to a "Hold" rating. Despite this downgrade, other analysts collect...